ArticleClinical rheumatology2026
Optimizing line blot assays: impact of band intensity adjustment on diagnostic performance in myositis autoantibodies testing.
Article in Clinical rheumatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionLine blot assays (LBA) have several limitations regarding diagnostic validity, as sensitivity and specificity vary considerably among antigens.
objectiveThe aim of this study was to assess whether the adjustment of each specific band intensity (BI) relative to the positive control band (PCB), combined with increasing the cut-off value from 15 to 20, improves the diagnostic performance of the LBA for detecting autoantibodies related to idiopathic inflammatory myopathies in our patient cohort.
methodsWe included all serum samples tested for myositis‑specific antibodies (MSA) and myositis‑associated antibodies (MAA) between January 2022 and April 2023 at the Immunology Department of Hospital Clínic of Barcelona. Two analyses were performed: Analysis A, using the manufacturer's recommended cut-off (BI ≥ 15), and Analysis B, applying the proposed BI adjustment relative to the PCB and raising the cut-off to 20 in samples that were positive in Analysis A.
resultsA total of 939 patients were included. Using Analysis A, 280/939 (29.8%) patients had at least one positive result, whereas 659/939 (70.2%) were negative for all MSA and MAA. After applying Analysis B, 151/280 (53.9%) remained positive, while 129/280 (46.1%) became negative. With Analysis A, sensitivity was 76%, specificity 75%, positive predictive value (PPV) 24%, and negative predictive value (NPV) 96%. Under Analysis B, sensitivity was 70%, specificity 89%, PPV 41%, and NPV 96%.
conclusionsApplying the proposed BI adjustment effectively removes weakly positive results with low specificity in an objective and reproducible manner, thereby increasing the overall specificity of the LBA. Key Points • Applying the proposed band intensity removes weakly positive results. • This approach enhances the specificity, and positive predictive value of a commercial line blot assay.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.